Advertisement

Hepatology International

, Volume 13, Issue 4, pp 395–398 | Cite as

The first Chinese guidelines on the Management of Ascites and its Related Complications in Cirrhosis: a great goal for a great country

  • P. AngeliEmail author
Commentary

Introduction

The guidelines developed by scientific societies and associations make sense if they can be interpreted and contextualized in the real-life conditions of different geographical areas and countries. For this to happen, they must bear in mind that: (a) the clinical characteristics of the same disease (liver cirrhosis in the case in point) can vary due to genetic, ethnic, and environmental factors and (b) many aspects of disease management strongly depend on how different health systems are organized. The Chinese Society of Hepatology takes credit for achieving this goal. The methodology adopted by the Society and its working team was rigorous and multidisciplinary. The final document may seem rather long and difficult to consult in clinical practice. The same criticism was voiced over the European Association for the Study of the Liver (EASL) guidelines [1], too. However, the topic is very broad and such guidelines should be used like a manual, ready to hand, that deals...

Notes

References

  1. 1.
    EASL Clinical Practice Guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53:397–417Google Scholar
  2. 2.
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151–7CrossRefPubMedGoogle Scholar
  3. 3.
    Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015;63:1272–84CrossRefPubMedGoogle Scholar
  4. 4.
    Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline. Management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57: 1651–1653CrossRefPubMedGoogle Scholar
  5. 5.
    Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258–66CrossRefPubMedGoogle Scholar
  6. 6.
    Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164–76CrossRefGoogle Scholar
  7. 7.
    Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, et al. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol 2014;20:11400–5CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018;391:2417–29CrossRefPubMedGoogle Scholar
  9. 9.
    Solà E, Solé C, Simón-Talero M, Martín-Llahí M, Castellote J, Garcia-Martínez R, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol 2018;69:1250–9CrossRefPubMedGoogle Scholar
  10. 10.
    Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018;391:2417–29CrossRefPubMedGoogle Scholar
  11. 11.
    Alessandria C, Elia C, Mezzabotta L, Risso A, Andrealli A, Spandre M et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis 2011;43:881–6PubMedGoogle Scholar
  12. 12.
    Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012;55:1172–81CrossRefPubMedGoogle Scholar
  13. 13.
    Rai N, Singh B, Singh A, Vijayvergiya R, Sharma N, Bhalla A et al. Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. Liver Int 2017;37:406–14CrossRefPubMedGoogle Scholar
  14. 14.
    Jia JD, Xie W, Ding HG, Mao H, Guo H, Li Y, et al. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: a prospective cohort study. Ann Hepatol 2017;16:123–32CrossRefPubMedGoogle Scholar
  15. 15.
    Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, et al. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterol 2018;18(1):137.  https://doi.org/10.1186/s12876-018-0857-0 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Fimiani B, Guardia DD, Puoti C, D’Adamo G, Cioffi O, Pagano A, et al. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study. Eur J Intern Med 2011;22:587–90CrossRefPubMedGoogle Scholar
  17. 17.
    Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363–8CrossRefPubMedGoogle Scholar
  18. 18.
    Rodriguez E, Henrique Pereira G, Solà E, Elia C, Barreto R, Pose E, et al. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: effects on kidney function and transplantation outcomes. Liver Transpl 2015;21:1347–54CrossRefPubMedGoogle Scholar
  19. 19.
    Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J. et al. on behalf of International Club of Ascites Global Study Group. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology 2018Google Scholar
  20. 20.
    Piano S, Bartoletti M, Tonon M, Baldassarre M, Chies G, Romano A, et al. Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. Gut 2018;67:1892–9CrossRefPubMedGoogle Scholar
  21. 21.
    Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818–24CrossRefPubMedGoogle Scholar
  22. 22.
    Moreau R, Elkrief L, Bureau C, Perarnau JM, Thévenot T, NORFLOCIR Trial Investigators et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology 2018;155:1816–27CrossRefPubMedGoogle Scholar
  23. 23.
    Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716–24CrossRefPubMedGoogle Scholar
  24. 24.
    Angeli P, Bernardi M. Reply to: prophylaxis of spontaneous bacterial peritonitis: is there still room for quinolones? J Hepatol 2019;5:25.  https://doi.org/10.1016/j.jhep.2019.01.011 (Epub ahead of print) CrossRefGoogle Scholar
  25. 25.
    Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015;62:968–74CrossRefPubMedGoogle Scholar
  26. 26.
    Piano S, Schmidt HH, Ariza X, Amoros A, Romano A, Hüsing-Kabar A et al. on behalf of EASL CLIF Consortium, European Foundation for the Study of Chronic Liver Failure (EF Clif). Association Between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome. Clin Gastroenterol Hepatol 2018;16: 1792–1800CrossRefPubMedGoogle Scholar
  27. 27.
    Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology 2016;63:983–92CrossRefPubMedGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2019

Authors and Affiliations

  1. 1.Internal Medicine and Hepatology Unit (UIMH), Dept of Medicine (DIMED)Padova University-Teaching HospitalPaduaItaly

Personalised recommendations